Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT01192633 Recruiting - Sarcoma Clinical Trials

Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma

GVPS
Start date: January 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate PFS of gemcitabine,vincristine and cisplatin as second line therapy in patients with sarcoma. 40 patients will be treated into this study.

NCT ID: NCT01132014 Completed - Ovarian Cancer Clinical Trials

Autologous OC-DC Vaccine in Ovarian Cancer

Start date: May 2010
Phase: Early Phase 1
Study type: Interventional

This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with intravenous Bevacizumab and cyclophosphamide or in combination with intravenous Bevacizumab, cyclophosphamide and aspirin. Study duration is 24 months.

NCT ID: NCT01111851 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting (CINV)

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.

NCT ID: NCT01074255 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Start date: April 2007
Phase: N/A
Study type: Observational

This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.

NCT ID: NCT01067989 Terminated - Chemotherapy Clinical Trials

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature. This study is meant to test the therapeutic potential of an anti-angiogenic treatment strategy by combining all these agents for metastatic breast cancer patients.

NCT ID: NCT01048463 Recruiting - Colorectal Cancer Clinical Trials

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

Start date: December 2009
Phase: Phase 3
Study type: Interventional

Malnutrition is frequently seen in patients on chemotherapy suffering from gastric/colorectal cancer and may worsen the outcome. EPA, a sort of ω-3 PUFA, can modulate immune system. EPA also antagonizes metabolic and inflammatory changes induced by the tumor. This study is to test whether EPA, in combination with enteral nutrition, can improve nutritional/immunologic status, quality of life, and reduce chemotherapy related side effects of these patients.

NCT ID: NCT01037933 Completed - Cancer Clinical Trials

Comedy in Chemotherapy (COMIC) Study

COMIC
Start date: February 2007
Phase: Phase 2
Study type: Interventional

Primary aims: To compare changes in (a) symptoms related to cancer and chemotherapy, (b) a marker of immune function (salivary immunoglobulin A), and (c) a hormonal marker of emotional stress (salivary cortisol) between two groups of patients who view a humorous or non-humorous DVD. Secondary aim: To describe the perception of patients, caregivers, and nurses regarding the overall intervention experience.

NCT ID: NCT01031498 Completed - Clinical trials for Acute Myelogenous Leukemia

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

NCT ID: NCT01023802 Completed - Breast Cancer Clinical Trials

The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

Start date: February 2009
Phase: N/A
Study type: Observational

In patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy molecular breast imaging (MBI) is an accurate test for assessing response rate to neoadjuvant therapy.

NCT ID: NCT01018758 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

NHLPal
Start date: July 2006
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).